GlassScriptPhysician profile
Natalie J Steinhoff
NPI 1588067375
$4,454.81
in general payments reported to CMS, 2019-2025
33 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $245 · 2021: $399 · 2022: $444 · 2023: $575 · 2024: $908 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.80 |
| Education | $125.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.71 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $526.08 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $453.07 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $275.83 | 2019-2025 | Nemluvio |
| Pfizer INC. | $226.05 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $191.10 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $187.08 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Kerecis Limited | $147.11 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Amgen INC. | $143.94 | 2021-2025 | Otezla |
| Incyte Corporation | $130.94 | 2022-2025 | Opzelura |
| Ucb, INC. | $115.39 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.10 | 2020-2024 | Jublia, Arazlo, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $109.77 | 2019-2023 | Dupixent |
| Sanofi-Aventis U.S. LLC | $104.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $102.83 | 2022-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $95.10 | 2021-2025 | Adbry |
| Allergan, INC. | $86.29 | 2019 | |
| Arcutis Biotherapeutics, INC. | $82.32 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.75 | 2023-2024 | Spevigo, Cyltezo |
| Organon LLC | $46.35 | 2025 | Vtama |
| Biofrontera INC. | $41.42 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $37.24 | 2019-2020 | |
| Dermavant Sciences, INC. | $35.77 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $31.69 | 2025 | Xtrac |
| Convatec INC. | $31.14 | 2025 | |
| Organogenesis INC. | $25.24 | 2023 | Puraply |
| Celgene Corporation | $23.45 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.15 | 2019 | |
| Urgo Medical North America, LLC | $17.34 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Bioventus LLC | $15.03 | 2022 | |
| Kyowa Kirin, INC. | $14.22 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.13 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Steinhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.